Khetan, RiyaDharmayanti, CintyaGillam, Todd A.Kübler, EricKlingler-Hoffmann, ManuelaRicciardelli, CarmelaOehler, Martin K.Blencowe, AntonGarg, SanjayAlbrecht, Hugo2022-10-042022-10-042022-05-102072-669410.3390/cancers14102362https://irf.fhnw.ch/handle/11654/33894https://doi.org/10.26041/fhnw-4301The five-year survival rate for women with ovarian cancer is very poor despite radical cytoreductive surgery and chemotherapy. Although most patients initially respond to platinum-based chemotherapy, the majority experience recurrence and ultimately develop chemoresistance, resulting in fatal outcomes. The current administration of cytotoxic compounds is hampered by dose-limiting severe adverse effects. There is an unmet clinical need for targeted drug delivery systems that transport chemotherapeutics selectively to tumor cells while minimizing off-target toxicity. G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, and many are overexpressed in solid tumors, including ovarian cancer. This review summarizes the progress in engineered nanoparticle research for drug delivery for ovarian cancer and discusses the potential use of GPCRs as molecular entry points to deliver anti-cancer compounds into ovarian cancer cells. A newly emerging treatment paradigm could be the personalized design of nanomedicines on a case-by-case basis.enGPCROvarian cancerChemoresistanceChemotherapy600 - Technik, Medizin, angewandte Wissenschaften01A - Beitrag in wissenschaftlicher Zeitschrift